Form 4: Vaxcyte COO Jim Wassil Sells Shares Under 10b5-1 Trading Plan

Vaxcyte's Chief Operating Officer, Jim Wassil, sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Jim Wassil, the Chief Operating Officer of Vaxcyte, Inc., sold shares of the company's common stock on June 3, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on May 23, 2023.
• A total of 2,990 shares were sold in multiple transactions at weighted-average prices of $71.384, $72.319, and $73.475.
• Following the reported transactions, Wassil beneficially owns 213,503 shares of Vaxcyte common stock.
• Wassil also acquired 1,041 shares under the Issuer's Employee Stock Purchase Plan on May 17, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The stock sale is part of a pre-arranged plan, mitigating negative implications. The acquisition of shares through the employee stock purchase plan is a slightly positive sign.

Positives

• The sales were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.
• Wassil acquired 1,041 shares under the Issuer's Employee Stock Purchase Plan on May 17, 2024.

Negatives

• The sale of shares by a high-ranking officer could be perceived negatively by some investors, although it was conducted under a pre-arranged plan.

Risks

• Executive stock sales can sometimes signal a lack of confidence in the company's future prospects, although this is mitigated by the 10b5-1 trading plan.

Industry Context

Insider trading activity is always closely watched in the biotech industry, especially for companies like Vaxcyte that are in the development stage. Sales under 10b5-1 plans are common and provide a structured way for insiders to diversify their holdings without raising concerns about trading on material non-public information.

Comparison to Industry Standards

• Comparing Wassil's transactions to other executives in similar biotech companies, the sale is relatively small and conducted under a pre-arranged plan, which is a common practice.
• Many biotech executives use 10b5-1 plans to manage their stock holdings, similar to executives at companies like Moderna or BioNTech.

Stakeholder Impact

• The stock sale could have a minor impact on shareholder sentiment, but the pre-arranged nature of the sale should alleviate concerns.
• Employees participating in the Employee Stock Purchase Plan may view the executive's stock sale with some caution.

Key Dates